Log In
Print this Print this

Factor IX-CTP

  Manage Alerts
Collapse Summary General Information
Company Opko Health Inc.
DescriptionLong-acting formulation of recombinant Factor IX developed using carboxyl terminal peptide (CTP) technology
Molecular Target Factor IX
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPreclinical
Standard IndicationHemophilia
Indication DetailsTreat hemophilia
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today